TG Therapeutics Inc (NASDAQ: TGTX) is a biopharmaceutical company focused on the development and commercialization of treatments for B-cell diseases and other serious conditions. The company generates revenue through product sales of its approved therapies, supported by third-party manufacturing, distribution, and commercialization arrangements. The 10-K filed 2026-02-27 covers the fiscal year ended December 31, 2025. The filing indicates TGTX is listed on the Nasdaq Capital Market. The company relies on contractual relationships with third parties for manufacturing, distribution, and supply chain functions. Intellectual property protection covering its products and product candidates is cited as a key business consideration. The filing references ongoing commercialization efforts and revenue generation from approved drug products, with financial performance and cash burn management identified as material operational focus areas.

Revenue model

Product sales of approved pharmaceutical therapies, supported by third-party manufacturing and distribution arrangements. The filing references revenue projections and commercialization efforts but does not provide specific revenue figures in the available excerpts.

Products and services

The filing references approved drug products and pipeline drug candidates focused on B-cell diseases and related serious conditions. Specific product names are not disclosed in the available filing excerpts.

Customers and end markets

The filing references commercialization of drug products but does not specify customer segments, end markets, or customer concentration data in the available excerpts.

Value-chain role

Drug developer and commercial-stage biopharmaceutical company. Relies on third-party contractors for manufacturing, distribution, and supply chain functions.

Geographic exposure

The filing does not provide geographic revenue breakdown or specific market footprint data in the available excerpts.

Source: SEC 10-K, filed 2026-02-27

Industry: Pharmaceutical Preparations Peers: Arcellx Inc Design Therapeutics Inc Editas Medicine Inc IGM Biosciences, Inc. Rocket Pharmaceuticals Inc Kura Oncology Inc Mirum Pharmaceuticals Inc Nuvalent, Inc Replimune Group Inc